000			01930 a2200541 4500
005			20250514015454.0
264		0	_c20020123
008			200201s 0 0 eng d
022			_a1526-9655
024	7		_a10.3816/clm.2001.n.005 _2doi
040			_aNLM _beng _cNLM
100	1		_aFoss, F M
245	0	0	_aBiological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. _h[electronic resource]
260			_bClinical lymphoma _cMar 2001
300			_a298-302 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aCombined Modality Therapy
650	0	4	_aDexamethasone _xtherapeutic use
650	0	4	_aDiphtheria Toxin _xadverse effects
650	0	4	_aDrug Hypersensitivity _xetiology
650	0	4	_aFemale
650	0	4	_aGlucocorticoids _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xadverse effects
650	0	4	_aImmunotoxins _xadverse effects
650	0	4	_aInterleukin-2 _xadverse effects
650	0	4	_aLymphocytes _ximmunology
650	0	4	_aLymphoma, T-Cell, Cutaneous _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aPrednisone _xtherapeutic use
650	0	4	_aPremedication
650	0	4	_aRecombinant Fusion Proteins _xadverse effects
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aSyndrome
650	0	4	_aTreatment Outcome
700	1		_aBacha, P
700	1		_aOsann, K E
700	1		_aDemierre, M F
700	1		_aBell, T
700	1		_aKuzel, T
773	0		_tClinical lymphoma _gvol. 1 _gno. 4 _gp. 298-302
856	4	0	_uhttps://doi.org/10.3816/clm.2001.n.005 _zAvailable from publisher's website
999			_c11622714 _d11622714